Inhibikase Therapeutics Inc (IKT)’s stock is trading at $1.81 at the moment marking a rise of 9.70% from the last session close. As of this writing, shares are priced at -48.14% less than their 52-week high of $3.49, and 36.09% over their 52-week low of $1.33. Based on the past 30-day period, the stock price is -2.58% below the high and +29.29% above the low.
The 200-day Simple moving average is often placed more emphasis on by traders because of daily price changes. Investors will use the SMA-200 in different situations in trading activity as a key indicator to determine their support and resistance levels, and at the moment, IKT’s SMA-200 is $1.7918.
IKT’s price to book ratio for the most recent quarter was 1.86, resulting in an 2.84 price to cash per share for the period.
How does Inhibikase Therapeutics Inc (IKT) stock rate among analysts? Buy, sell, or hold?
The key to trading is to concentrate on the future rather than on the past. During uncertain times, it can be hard to make decisions. The analysts who understand how a market works are usually the most accurate at forecasting its future. Currently, there are 5 brokerage firms that recommend the stock as a Strong Buy. The ratings are commonly aggregated into a single number between 1 and 5. Buy or strong buy is scored 5, outperform is scored 4, hold is scored 3, underperform is scored 2 and strong sell is 1. Using a scale of 1-5, the current average recommendation is 4.60 in simple terms.
Inhibikase Therapeutics Inc (NASDAQ: IKT) Ownership Details
I will give a breakdown of the key shareholders in Inhibikase Therapeutics Inc (IKT). Recent figures show that the company’s insiders hold 8.01% of shares. A total of 80 institutional investors hold shares in the company, making 48.48% of its stock and 52.70% of its float.
Sep 30, 2025, it was reported that the Company’s largest institutional holder is Sands Capital Alternatives, LLC holding total of 10.95 shares that make 14.57% of the company’s total number of shares and are currently priced at 19.93 million.
The securities firm Soleus Capital Management, L.P. holds 6.33 shares of IKT, making it the second largest institutional shareholder. Taking this into account, the holding percentage comes to 8.41%, and the holding percentage of shares is valued at 11.51 million.
An overview of Inhibikase Therapeutics Inc’s technicals
In order to learn about trade movements and investor behavior, it is best to analyze the short, medium, and long term technical indicators along with the average volume of a stock. A 20-day average of the stock’s daily volume suggests Inhibikase Therapeutics Inc (IKT) traded 514,697 shares per day, with a moving average of $1.5618 and price change of +0.2700. With the moving average of $1.5547 and a price change of +0.2100, about 354,357 shares changed hands on average over the past 50 days. Finally, IKT’s 100-day average volume is 235,428 shares, alongside a moving average of $1.6065 and a price change of +0.0100.
